Bristol Myers Squibb said it is decreasing the maximum aggregate purchase price of the Pool 1 Notes from the previously announced $4,000,000,000 to an amount sufficient to accept for purchase all Pool 1 Notes that were validly tendered and not validly withdrawn prior to the Early Tender Deadline.

1. 01

   Bristol Myers Squibb said it is decreasing the maximum aggregate purchase price of the Pool 1 Notes from the previously announced $4,000,000,000 to an amount sufficient to accept for purchase all Pool 1 Notes that were validly tendered and not validly withdrawn prior to the Early Tender Deadline.

2. 02

   The company is increasing the maximum aggregate purchase price of the Pool 2 Notes from the previously announced $3,000,000,000 to an amount sufficient to accept for purchase all Pool 1 through 4 Notes and up to $250,000,000 in principal amount of its 5.900% Notes due 2033.

3. 03

   Bristol Myers Squibb said that as of the Early Tender Deadline, its 5.900% Notes due 2033 received tenders of $493,578,000 of the $1,000,000,000 principal amount outstanding, and that it expects to accept these Notes on a prorated basis because the amount exceeds $250,000,000.

4. 04

   The company said it has exercised its Early Settlement Right, with the Early Settlement Date occurring on November 20, 2025, and it expects there will be no Final Settlement Date and will not accept any tenders of Notes after the Early Tender Deadline.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.